{"created":"2023-05-15T11:23:24.709195+00:00","id":3002,"links":{},"metadata":{"_buckets":{"deposit":"65bcfa2b-c784-414f-bf7d-45293021aca7"},"_deposit":{"created_by":1,"id":"3002","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"3002"},"status":"published"},"_oai":{"id":"oai:showa.repo.nii.ac.jp:00003002","sets":["1:6:244:245"]},"author_link":["10353","10356","10352","10351","10357","10348","10346","10349","10355","10347","10354","10350"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-02"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"42","bibliographicPageStart":"35","bibliographicVolumeNumber":"79","bibliographic_titles":[{"bibliographic_title":"昭和学士会雑誌"}]}]},"item_10002_description_6":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"パクリタキセルおよびカルボプラチン療法（TC療法）は，卵巣癌の標準治療として広く受け入れられている．われわれは，卵巣がん患者における術後補助化学療法後の増悪に関連する因子の探索を目的に解析を行った．卵巣がんと診断され，カルボプラチンを含む化学療法を施行した患者72名を対象とした．エンドポイントは増悪とした．腫瘍減量術施行時の患者背景に関してCox比例ハザードモデルを用い，増悪因子を抽出した．追跡期間の中央値は22か月（3〜96）であった．72人のうち増悪した患者は35人，2年累積増悪率は50.8％であった．また，増悪した患者（n＝35）のうち，32人（91.4％）は2年以内に増悪していた．増悪に関連する因子としてAlb，CA125，病理組織，残存腫瘍の有無の4因子が抽出された．多変量解析の結果，術後補助化学療法後の増悪に独立して関連する有意な因子として残存腫瘍の有無が抽出され，残存腫瘍のある患者はない患者と比較して2.681倍増悪リスクが高いことが示された（p＜0.05）．医療者は本情報を共有し，患者の適正なリスクマネージメントを行うべきである．","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"昭和大学学士会"}]},"item_10002_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.14930/jshowaunivsoc.79.35"}}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2187-719X"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"内藤, 由貴"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"戸村, 和希"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"須永, 登美子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"永谷, 明子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"内田, 展"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"田中, 広紀"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"粟屋, 真理子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"秋山, 菜央"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"楠, 裕美子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小川, 公一"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"向後, 麻里"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"佐々木, 忠徳"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-27"}],"displaytype":"detail","filename":"79_35.pdf","filesize":[{"value":"278.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"79_35.pdf","url":"https://showa.repo.nii.ac.jp/record/3002/files/79_35.pdf"},"version_id":"56227c71-aa68-4208-ac55-885022016731"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper"}]},"item_title":"カルボプラチンを含む術後補助化学療法を施行した卵巣がん患者における増悪因子の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"カルボプラチンを含む術後補助化学療法を施行した卵巣がん患者における増悪因子の検討"}]},"item_type_id":"10002","owner":"1","path":["245"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-08-27"},"publish_date":"2019-08-27","publish_status":"0","recid":"3002","relation_version_is_last":true,"title":["カルボプラチンを含む術後補助化学療法を施行した卵巣がん患者における増悪因子の検討"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T12:35:20.897065+00:00"}